Ottawa, March 18, 2026 – Canada must strengthen its approach to pharmaceutical innovation in a rapidly evolving global environment. Today’s announcement is an important and much awaited step in that direction.
IMC welcomes the federal government’s creation of the Pharmaceutical and Life Sciences Sector Task Force. It reflects a recognition of the challenges and opportunities facing the sector, and the need for unified, pan-Canadian action.
“The moment is urgent,” says Dr. Bettina Hamelin, President and CEO. “Global shifts – particularly the new U.S. most-favoured-nation (MFN) drug pricing policy – are already influencing investment and launch decisions for new medicines in Canada. The task force will need to move quickly, with focus and ambition.”
IMC and its members stand ready to contribute. We are committed to bringing forward evidence, expertise, and practical recommendations to support a Canadian approach that will protect patients, strengthen innovation, and reinforce Canada’s role as a reliable partner in global health.
